Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 12/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 12/20 | 1.00 |
| ▸ | RELA | Q04206 | 12/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586683 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELAGAABTK | |
| SCHEMBL14586681 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELAGAABTK | |
| SCHEMBL6917362 | 0.86 | NFKB1 (0.75) | NFKB1NFKB2RELAGAABTK | |
| SCHEMBL22227389 | 0.86 | NFKB1 (0.75) | NFKB1NFKB2RELAGAABTK | |
| SCHEMBL25567964 | 0.86 | NFKB1 (0.75) | NFKB1NFKB2RELAGAABTK | |
| SCHEMBL5600742 | 0.79 | NFKB1 (1.00) | NFKB1NFKB2RELAGAA | |
| SCHEMBL8881361 | 0.78 | NFKB1 (0.64) | NFKB1NFKB2RELAGAABTK | |
| SCHEMBL10423458 | 0.78 | NFKB1 (0.64) | NFKB1NFKB2RELAGAABTK | |
| SCHEMBL8280815 | 0.77 | NFKB1 (0.62) | NFKB1NFKB2RELAGAABTK | |
| SCHEMBL21052085 | 0.76 | NFKB1 (0.60) | NFKB1NFKB2RELAGAABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20240270755-A1 | SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-15 | — | — | US | disclosed |
| EP-4317153-A1 | ABHD6 ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20240010658-A1 | ABHD6 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| CN-117120435-A | ABHD6 antagonists | 小野药品工业株式会社 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022211060-A1 | ABHD6 ANTAGONIST | 小野薬品工業株式会社 | 2022-10-06 | — | — | WO | disclosed |
| EP-1537066-B1 | CYCLOPENTENONE DERIVATIVES AS POTENT ACTIVATORS OF HSF-1 | BIOGEM S C AR L (IT) | 2017-01-25 | — | — | EP | disclosed |
| EP-1537066-B1 | CYCLOPENTENONE DERIVATIVES AS POTENT ACTIVATORS OF HSF-1 | BIOGEM S C AR L (IT) | 2017-01-25 | — | — | EP | disclosed |
| US-7183440-B2 | Pharmaceutically useful compounds | CHARTERHOUSE THERAPEUTICS LTD (GB) | 2007-02-27 | — | — | US | disclosed |
| US-7183440-B2 | Pharmaceutically useful compounds | CHARTERHOUSE THERAPEUTICS LTD (GB) | 2007-02-27 | — | — | US | disclosed |
| US-20060040869-A1 | Pharmaceutically useful compounds | BIOGEM S.C.A.R.L. (IT) | 2006-02-23 | — | — | US | disclosed |
| EP-1537066-A2 | IMPROVEMENTS IN PHARMACEUTICALLY USEFUL COMPOUNDS | Charterhouse Therapeutics Ltd. (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013077-A2 | CYCLOPENTANONE AND CYCLOPENTANONE DERIVATIVES AS POTENT ACTIVATORS OF HSF-1 | CHARTERHOUSE THERAPEUTICS LTD (GB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040869-A1 | Pharmaceutically useful compounds | MC2R, CRKL, NPY2R | NFKB1 2975/4885NFKB2 2252/4885RELA 3671/4885 |
| US-20240010658-A1 | ABHD6 ANTAGONIST | ABHD6, ABHD16A, ABHD12 | NFKB1 2200/4885NFKB2 1889/4885RELA 2378/4885 |
| US-20240270755-A1 | SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS | ABHD6, ABHD16A, PITHD1 | NFKB1 2374/4885NFKB2 2230/4885RELA 2960/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | NFKB1 2817/4885NFKB2 2633/4885RELA 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.